Medovex (MDVXU) Stock Price, News & Analysis

Company Overview

Medovex Corp. is a development-stage company. The Company focuses on obtaining, developing and commercializing various intellectual property rights (patents, patent applications and knowhow) in the medical technology area, with particular focus on the development of medical devices. It focuses on development and commercialization of the DenerveX System, which consists of the DenerveX Device and the DenerveX Pro-40 power generator (DenerveX). DenerveX is a device that is intended to be used in the treatment of conditions resulting from the degeneration of joints in the spine that cause back pain. The DenerveX Pro-40 Power Generator is the power source for the DenerveX System. The system works in synchronization to deliver controlled and precise therapy to patients with facet joint pain. DenerveX combines two procedures in one: capsular tissue removal through a light tissue scraping action and radio ablation denervation. DenerveX is commercially not available in the United States.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 880,077 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MDVXU Stock Analysis - Frequently Asked Questions

When did Medovex IPO?

Medovex (MDVXU) raised $8 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 1,400,000 shares at $5.75 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MDVXU
• CIK: 1591165
• Web: www.MEDOVEX.com
• Phone: +1-404-3936989
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A